Teriparatide and osseous regeneration in the oral cavity.

Bashutski JD, Eber RM, Kinney JS, Benavides E, Maitra S, Braun TM, Giannobile WV, McCauley LK

The New England journal of medicine16 Oct 2010Cited by 192 (Europe PMC)

PMID20950166PMCIDPMC5695223DOI10.1056/nejmoa1005361PepBankPUB-20950166

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with periodontitis, teriparatide increased alveolar bone gain at 1 year to 29% versus 3% with placebo.
In plain wordsIn patients with periodontitis, teriparatide increased jaw bone gain more than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseAlveolar bone gain
Study
n = 40
Comparator
Placebo
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · injection · 6 weeksAs given in this study (human).
Measurements
Mean linear gain in alveolar bone at 1 year
29%
Teriparatide group
Mean linear gain in alveolar bone at 1 year
3%
Placebo group
Source sentences
Summary
Radiographic linear resolution of osseous defects was significantly greater after teriparatide therapy than after placebo beginning at 6 months, with a mean linear gain in bone at 1 year of 29% as compared with 3% (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 patients with severe, chronic periodontitis underwent periodontal surgery and received daily injections of teriparatide (20 μg) or placebo, along with oral calcium (1000 mg) and vitamin D (800 IU) supplementation, for 6 weeks.
Summary · context
The patients were followed for 1 year.
Report a problemFND-2095016601
02HumanNon-randomized trialEfficacy outcome
In patients with periodontitis, teriparatide reduced probing depth by 33% versus 20% with placebo at 1 year.
In plain wordsIn patients with periodontitis, teriparatide reduced gum pocket depth more than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePeriodontal probing depth
Study
n = 40
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · injection · 6 weeksAs given in this study (human).
Measurements
Reduction in periodontal probing depth at 1 year
33%
Teriparatide group, target lesions
Reduction in periodontal probing depth at 1 year
20%
Placebo group, target lesions
Reduction in periodontal probing depth at 1 year
2.42 mm
Teriparatide group, target lesions
Reduction in periodontal probing depth at 1 year
1.32 mm
Placebo group, target lesions
Source sentences
Summary
Clinical improvement was greater in patients taking teriparatide than in those taking placebo, with a reduction in periodontal probing depth of 33% versus 20% (2.42 mm vs. 1.32 mm) and a gain in clinical attachment level of 22% versus 7% (1.58 mm vs. 0.42 mm) in target lesions at 1 year (P = 0.02 for both comparisons).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 patients with severe, chronic periodontitis underwent periodontal surgery and received daily injections of teriparatide (20 μg) or placebo, along with oral calcium (1000 mg) and vitamin D (800 IU) supplementation, for 6 weeks.
Summary · context
The patients were followed for 1 year.
Report a problemFND-2095016602
03HumanNon-randomized trialEfficacy outcome
In patients with periodontitis, teriparatide increased clinical attachment by 22% versus 7% with placebo at 1 year.
In plain wordsIn patients with periodontitis, teriparatide improved tooth attachment more than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseClinical attachment level
Study
n = 40
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · injection · 6 weeksAs given in this study (human).
Measurements
Gain in clinical attachment level at 1 year
22%
Teriparatide group, target lesions
Gain in clinical attachment level at 1 year
7%
Placebo group, target lesions
Gain in clinical attachment level at 1 year
1.58 mm
Teriparatide group, target lesions
Gain in clinical attachment level at 1 year
0.42 mm
Placebo group, target lesions
Source sentences
Summary
Clinical improvement was greater in patients taking teriparatide than in those taking placebo, with a reduction in periodontal probing depth of 33% versus 20% (2.42 mm vs. 1.32 mm) and a gain in clinical attachment level of 22% versus 7% (1.58 mm vs. 0.42 mm) in target lesions at 1 year (P = 0.02 for both comparisons).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 patients with severe, chronic periodontitis underwent periodontal surgery and received daily injections of teriparatide (20 μg) or placebo, along with oral calcium (1000 mg) and vitamin D (800 IU) supplementation, for 6 weeks.
Summary · context
The patients were followed for 1 year.
Report a problemFND-2095016603
04HumanNon-randomized trialEfficacy outcome
In patients with periodontitis, other assessed variables did not differ significantly between teriparatide and placebo.
In plain wordsIn patients with periodontitis, other assessed measures did not differ significantly between teriparatide and placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeOther assessed variables
Study
n = 40
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · injection · 6 weeksAs given in this study (human).
Source sentences
Summary
No significant differences were noted with respect to the other variables that were assessed.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included clinical variables, bone turnover markers in serum and oral fluid, systemic bone mineral density, and quality of life.
Summary · context
A total of 40 patients with severe, chronic periodontitis underwent periodontal surgery and received daily injections of teriparatide (20 μg) or placebo, along with oral calcium (1000 mg) and vitamin D (800 IU) supplementation, for 6 weeks.
Summary · context
The patients were followed for 1 year.
Report a problemFND-2095016605

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

05HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialSafety outcome
In patients with periodontitis, no serious adverse events were reported during the study of teriparatide and placebo.
In plain wordsIn patients with periodontitis, the teriparatide and placebo study reported no serious adverse events.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableSerious adverse events
Study
n = 40
Outcome group
Adverse events · Whole body
Source sentences
Summary
No serious adverse events were reported; however, the number of patients in the study was small.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 40 patients with severe, chronic periodontitis underwent periodontal surgery and received daily injections of teriparatide (20 μg) or placebo, along with oral calcium (1000 mg) and vitamin D (800 IU) supplementation, for 6 weeks.
Summary · context
The patients were followed for 1 year.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2095016604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT00277706

Impact of Parathyroid Hormone (PTH) on Osseous Cavity

University of Michigann = 40Aug 2004 to Jul 2009

Bone Loss · Periodontitis

Trial page ClinicalTrials.govUpdated 7 Oct 2009

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.